Literature DB >> 12195317

[Intravitreal injection of rt-PA and gas in the management of minor submacular haemorrhages secondary to age-related macular degeneration].

Lars-Olof Hattenbach1, Marion Brieden, Frank Koch, Hermann Gümbel.   

Abstract

BACKGROUND: Subfoveal haemorrhage is a serious complication of choroidal neovascularization in age-related macular degeneration (ARMD). Recent studies have demonstrated that intravitreal injections of the fibrinolytic agent recombinant tissue plasminogen activator (rt-PA) and expansile gas may be effective in displacing submacular blood and facilitating visual improvement. However, in most of these studies, this technique has been used for the management of major haemorrhages. The purpose of our study was to investigate the efficacy of treating minor subfoveal haemorrhages with intravitreal rt-PA and pneumatic displacement. PATIENTS AND METHODS: In a prospective study, 25 consecutive eyes of 25 patients with recent (</= 28 days) subfoveal haemorrhage secondary to ARMD and severe visual loss were treated with intravitreous injections of rt-PA (50 micro g) and sulfur hexafluoride (0,5 ml). The extent of the haemorrhage ranged from R to 2 disc areas. Patient follow-up ranged between 4 and 18 months.
RESULTS: Best postoperative visual acuity compared with preoperative visual acuity was improved by two or more Snellen lines in 11 of 25 eyes (44 %). Seven eyes (28 %) maintained this level at the final visit. Duration of haemorrhage was associated with a better gain of lines of vision. In a subgroup of 9 eyes with duration of haemorrhage </= 14 days, 7 (78 %) improved by two or more Snellen visual acuity lines, whereas only 4 of 16 eyes (25 %) with duration of haemorrhage > 14 days showed a comparable outcome (p = 0.017). There were no side effects or complications.
CONCLUSIONS: Our findings suggest that intravitreous injections of rt-PA and sulfur hexafluoride are of value for an improved and accelerated visual recovery in ARMD patients with minor subfoveal haemorrhages. Duration of haemorrhage </= 14 is associated with a better gain of lines of vision. Final visual outcome, however, is limited by the underlying ARMD. In addition, a rapid displacement of subfoveal haemorrhages may reveal discrete choroidal neovascular membranes amenable to further treatment. The complication rate of this therapeutic approach appears to be low.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12195317     DOI: 10.1055/s-2002-33584

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  5 in total

1.  [Stability of postoperative visual acuity after rt-PA -SF6-treatment of submacular hemorrhage in age-related macular degeneration].

Authors:  A Steller; E Gerke
Journal:  Ophthalmologe       Date:  2004-05       Impact factor: 1.059

2.  Vitrectomy for the treatment of submacular hemorrhages from macular degeneration: a comparison of submacular hemorrhage/membrane removal and submacular tissue plasminogen activator-assisted pneumatic displacement.

Authors:  John T Thompson; Raymond N Sjaarda
Journal:  Trans Am Ophthalmol Soc       Date:  2005

3.  [Combined intravitreal injection of bevacizumab and SF6 gas for treatment of submacular hemorrhage secondary to age-related macular degeneration].

Authors:  F Höhn; A Mirshahi; L-O Hattenbach
Journal:  Ophthalmologe       Date:  2010-04       Impact factor: 1.059

Review 4.  [Management of submacular hemorrhage : What, when, how?]

Authors:  Lars-Olof Hattenbach; Salvatore Grisanti; Nicolas Feltgen; Argyrios Chronopoulos
Journal:  Ophthalmologe       Date:  2020-09       Impact factor: 1.059

Review 5.  Comparison of subretinal versus intravitreal injection of recombinant tissue plasminogen activator with gas for submacular hemorrhage secondary to wet age-related macular degeneration: treatment outcomes and brief literature review.

Authors:  Paris Tranos; Georgios N Tsiropoulos; Spyridon Koronis; Athanasios Vakalis; Solon Asteriadis; Panagiotis Stavrakas
Journal:  Int Ophthalmol       Date:  2021-07-30       Impact factor: 2.031

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.